TABLE 1.

Summary and characteristics of included studies exploring discontinuation or nonadherence across BMI categories or degree of self‐reported AIWG.

Study	Dx	Country of study	Objective of study	% Male	Mean age ± SD	N	Study type	Antipsychotic use timeframe	Definition of nonadherence/discontinuation in study	Nonadherence/discontinuation based on or proxy for AIWG used in meta‐analysis	Other metabolic variables considered in relation to treatment discontinuations
Doane 2020	SCZ	US	Online survey exploring attitudes towards AP treatment, among individuals who have been using APs for at least a 12‐month period at the time of survey	50	41.9 ± 11.0	200	Cross sectional (survey data)	NR – but SCZ dx for at least 1 year	Discontinuation of AP medication across degree of self‐reported weight gain: no weight gain or non‐bothersome weight gain, versus somewhat bothersome or very/extremely bothersome weight gain	Discontinuation in those reporting bothersome weight gain: 102/124 Discontinuation in those without weight gain or with non‐bothersome weight gain: 48/76	N
Sliwa 2014	SCZ	Multiple countries (Costa, Rica, Mexico, Romania, Russia, Ukraine, South Africa, Korea, Taiwan, US)	Post hoc analysis examining metabolic treatment‐related adverse events across BMI categories	59	37.3 ± 10.58	644 (29 of these individuals are in underweight category and are not relevant to this study)	Multicentre open‐label transition and extension data from RCT examining treatment with paliperidone palmitate (PP); only patients consistently treated with PP across all study phases were included in the analysis	Median duration of exposure to PP: 204 days (6 to 1009 days)	Discontinuation by patient choice across BMI categories	Overweight: 1/232 Obese: 0/154 Normal weight: 0/229 Overweight and obese combined: 1/386	N
Weiden 2004	SCZ	US	National survey examining self‐report of AP non‐compliance across BMI categories, and in relation to self‐report of distress around weight gain	NR directly (included in the logistic regression model)	NR directly (included in the logistic regression model)	239	Cross sectional (survey data)	NR directly (logistic regression model)	AP non‐compliance reported across BMI categories and according to subjective distress over “weight gain.” Non‐compliance was defined as “self‐report of missing any AP medication in the previous month”	Overweight: 34/88 Obese: 41/89 Normal weight: 16/62 Overweight and obese combined: 75/177 The total number of events in each group are approximations so that the reported OR could be reflected in the meta‐analysis.	N

Abbreviations: AP, antipsychotic; BMI, body mass index; NR, not reported; PP, paliperidone palmitate; SCZ, schizophrenia.